Usana Health Sciences (STU:USJ) Return-on-Tangible-Equity: -39.36% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:USJ Usana Health Sciences Inc STU:USJ
65 GF Score
Price €12.40
GF Value €29.53
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Usana Health Sciences Return-on-Tangible-Equity?

Usana Health Sciences STU:USJ +3.33% 65 Return-on-Tangible-Equity is -39.36% as of Jun. 2026. GuruFocus rates STU:USJ with a GF Score™ of 65/100 and a GF Value™ of €29.53 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 1,891 Consumer Packaged Goods companies, Usana Health Sciences ranks worse than 86.67% on this metric.

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Usana Health Sciences's annualized net income for the quarter that ended in Jun. 2026 was €-97.0 Mil. Usana Health Sciences's average shareholder tangible equity for the quarter that ended in Jun. 2026 was €246.6 Mil. Therefore, Usana Health Sciences's annualized Return-on-Tangible-Equity for the quarter that ended in Jun. 2026 was -39.36%.

The historical rank and industry rank for Usana Health Sciences's Return-on-Tangible-Equity or its related term are showing as below:

STU:USJ' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -10.88   Med: 26.21   Max: 40.07
Current: -10.88

During the past 13 years, Usana Health Sciences's highest Return-on-Tangible-Equity was 40.07%. The lowest was -10.88%. And the median was 26.21%.

STU:USJ's Return-on-Tangible-Equity is ranked worse than
86.67% of 1891 companies
in the Consumer Packaged Goods industry
Industry Median: 8.01 vs STU:USJ: -10.88

Usana Health Sciences  (STU:USJ) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Usana Health Sciences Return-on-Tangible-Equity Related Terms


Usana Health Sciences Return-on-Tangible-Equity Historical Data

* Premium members only.

The historical data trend for Usana Health Sciences's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Usana Health Sciences Return-on-Tangible-Equity Chart

Usana Health Sciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 32.70 19.54 15.08 12.58 4.09

Usana Health Sciences Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.50 -10.56 -2.80 11.23 -39.36

STU:USJ vs NATR, BYND, BGS: Return-on-Tangible-Equity Comparison

For the Packaged Foods subindustry, Usana Health Sciences's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Usana Health Sciences Return-on-Tangible-Equity vs Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Usana Health Sciences's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Usana Health Sciences's Return-on-Tangible-Equity falls into.


STU:USJ
65GF Score
Usana Health Sciences Inc STU:USJ
Return-on-Tangible-Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Usana Health Sciences Return-on-Tangible-Equity Calculation

Usana Health Sciences's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2025 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=9.189/( (225.493+223.74 )/ 2 )
=9.189/224.6165
=4.09 %

Usana Health Sciences's annualized Return-on-Tangible-Equity for the quarter that ended in Jun. 2026 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Jun. 2026 )  (Q: Mar. 2026 )(Q: Jun. 2026 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Jun. 2026 )  (Q: Mar. 2026 )(Q: Jun. 2026 )
=-97.044/( (239.192+253.934)/ 2 )
=-97.044/246.563
=-39.36 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Jun. 2026) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.

What does a Return-on-Tangible-Equity of -39.36% mean?
Usana Health Sciences (STU:USJ) has a Return-on-Tangible-Equity of -39.36% as of Jun. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Usana Health Sciences and its competitors. According to the industry distribution chart, Usana Health Sciences ranks #1639 out of 1891 companies in the Consumer Packaged Goods industry, placing it in the top 86.7%.
Is Usana Health Sciences' Return-on-Tangible-Equity too high?
Usana Health Sciences' current Return-on-Tangible-Equity is -39.36%. Based on the distribution chart, Usana Health Sciences ranks #1639 out of 1891 companies in the Consumer Packaged Goods industry, which is in the bottom quartile relative to peers. Overall, Usana Health Sciences has a GF Score™ of 65/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Usana Health Sciences' Return-on-Tangible-Equity compare to NATR and BYND?
According to the Consumer Packaged Goods industry distribution chart, Usana Health Sciences ranks #1639 out of 1891 companies for Return-on-Tangible-Equity. This places Usana Health Sciences in the lower half of its industry. The industry median Return-on-Tangible-Equity is 8.01. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Consumer Packaged Goods company?
The median Return-on-Tangible-Equity among Consumer Packaged Goods companies is 8.01, based on 1,891 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Usana Health Sciences and its competitors. For the Consumer Packaged Goods industry, the median Return-on-Tangible-Equity is 8.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Usana Health Sciences's current Return-on-Tangible-Equity is -39.36%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Usana Health Sciences stock overvalued right now?
Based on GuruFocus' analysis, Usana Health Sciences (STU:USJ) is currently considered Possible Value Trap. The stock's GF Value™ is €29.53, compared to a current price of €12.40 — trading 58% below its estimated fair value. The current Return-on-Tangible-Equity is -39.36%. Usana Health Sciences' overall GF Score™ is 65/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Usana Health Sciences (STU:USJ), the current Return-on-Tangible-Equity is -39.36% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Usana Health Sciences (STU:USJ) Overvalued in 2026?

Based on GuruFocus' analysis, Usana Health Sciences stock appears to be undervalued. The current stock price of €12.40 is trading 58% below its estimated GF Value™ of €29.53. GuruFocus considers Usana Health Sciences to be Possible Value Trap.

Key valuation signals for STU:USJ:

  • Return-on-Tangible-Equity: -39.36%
  • GF Value™: €29.53 vs. price of €12.40 (58% below fair value)
  • GF Score™: 65/100 with 5 warning signs

No single metric tells the full story. See the STU:USJ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Usana Health Sciences Business Description

Other Exchanges USNA:USAUSJ:Germany
Address 3838 West Parkway Boulevard, Salt Lake City, UT, USA, 84120
Usana Health Sciences Inc develops and manufactures high-quality nutritional supplements, functional foods, and personal care products that are sold throughout the world. The company has developed and manufactured high-quality, science-based nutritional, personal care, and skincare products with a primary focus on promoting long-term health and wellness. The Company's reporting units for goodwill purposes are tied to its reportable segments: Core nutritional and Hiya direct-to-consumer. The core nutritional segment consists of three individual reporting units that are determined based on the operational nature of the business: Buy-Sell, China, and India. Geographically, it is in Asia Pacific, the Americas, and Europe. With the majority of revenue from Asia Pacific(Greater China).
65GF Score

Get the complete analysis for STU:USJ

Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€12.40
Price
€29.53
GF Value